|Bid||56.00 x 100|
|Ask||71.49 x 100|
|Day's Range||69.63 - 72.18|
|52 Week Range||11.41 - 75.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.00|
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 17. Over the last one-month, outflows of investor capital in ETFs holding NKTR totaled $615 million.
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
NEW YORK, NY / ACCESSWIRE / January 10, 2018 / U.S. markets continued to climb to new record highs as we enter into earnings season. Major financial companies, BlackRock, J.P. Morgan Chase and Wells Fargo, ...
These two biotechs have promising new opioid drugs. But one appears to be the better pick for investors in the new year.
SAN FRANCISCO , Jan. 3, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 36th Annual J.P. Morgan Healthcare ...
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on December 7. Over the last one-month, outflows of investor capital in ETFs holding NKTR totaled $1.11 billion.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Nektar Therapeutics Here are 5 ETFs with the largest exposure to NKTR-US. Comparing the performance and risk of Nektar Therapeutics with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Nektar Therapeutics reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Nektar Therapeutics – Pfizer Inc. and Astrazeneca PLC Sponsored ADR (PFE-US and AZN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 152.93 million, Net ... Read more (Read more...)
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Bristol-Myers Squibb, Incyte, and Nektar Therapeutics could provide the biggest fireworks next year on the immunotherapy scene.
The market leaders have shifted since the first half of year. One way or another healthcare is going to see some big changes, so it’s a good time to position yourself in solid healthcare firms that will win, regardless of Washington. The following are my top seven A-rated healthcare stocks to buy now.
NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Sage Therapeutics headed higher on Thursday and hit a brand new high after announcing that its depressive disorder MDD treatment SAGE-217 had seen positive ...
Nektar Therapeutics (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hertz ...
Nektar Therapeutics' (NKTR) NKTR-181 has already received fast-track designation from the FDA (U.S. Food & Drug Administration).
Nektar Therapeutics (NKTR) plans to submit an NDA (New Drug Application) with the FDA (U.S. Food & Drug Administration) for late-stage chronic pain drug NKTR-118 by April 2018.